Skip to main content

Table 2 Adverse events (>10% of patients in any group) from a phase 1 study of CAD106 in patients with mild-to-moderate Alzheimer’s disease during the 52-week study period

From: Active immunotherapy options for Alzheimer’s disease

  Cohort 1 Cohort 2
Event CAD106 50 μg (n = 24) Placebo (n = 7) CAD106 150 μg (n = 22) Placebo (n = 5)
Any serious adverse event 4 (17) 1 (14) 4 (18) 0
Any adverse events 23 (96) 6 (86) 22 (100) 5 (100)
 Injection site erythema 1 (4) 1 (14) 14 (64) 0
 Nasopharyngitis 10 (42) 2 (29) 3 (14) 0
 Fatigue 7 (29) 0 4 (18) 1 (20)
 Nausea 4 (17) 2 (29) 3 (14) 0
 Chills 1 (4) 0 6 (27) 0
 Headache 5 (21) 0 4 (18) 1 (20)
 Diarrhea 3 (13) 1 (14) 0 1 (20)
 Vomiting 2 (8) 1 (14) 3 (14) 1 (20)
 Fever 1 (4) 0 4 (18) 0
 Injection site pain 0 0 4 (18) 0
 Myalgia 4 (17) 0 0 0
 Fall 3 (13) 1 (14) 1 (5) 0
 Back pain 3 (13) 0 3 (14) 0
 Rhinitis 3 (13) 0 0 0
  1. Data presented as n (%). Reprinted from [21]. © 2012, with permission from Elsevier.